ArticleBritish journal of cancer2026
Galectin-9-driven immunosuppressive macrophage population shapes the lymph node metastatic microenvironment.
Article in British journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- From Glycocode to Precision Oncology: Therapeutic Strategies Targeting Aberrant O-GalNAc Glycosylation in Cancer.Chemical reviews · 2026Review
- Single-cell omics in tumor lymph node metastasis: mechanisms and therapeutic implications.Molecular cancer · 2026Review
- Galectins at the crossroads of tumor immunity, metabolism, and metastasis: mechanisms, therapeutic resistance, and translational opportunities.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundLymph node (LN) metastasis is not only a prognostic indicator but also a driver of systemic immune suppression. However, the mechanisms of immune escape within LNs remain unclear.
methodsOur pan-cancer single-cell transcriptomic analysis integrated public and in-house datasets from 11 cancer types, comprising 859,744 cells across 132 samples. We subsequently applied unsupervised clustering and cell-type annotation to identify dominant immunosuppressive cell populations within metastatic lymph nodes. Focused transcriptomic and pathway enrichment analyses were used to characterize the molecular features of these populations. Mechanistic studies, including in vitro and in vivo functional assays, were conducted to elucidate the signaling pathways underlying their immunoregulatory activity.
resultsOur analysis revealed that LN metastases exhibit a profoundly immunosuppressive microenvironment compared to primary tumors, characterized by: (1) Significant enrichment of an IL-10-producing macrophage subpopulation (Galectin-9
conclusionOur study identifies a Galectin-9/BTK/STAT3 axis that drives macrophage-mediated immune suppression in LN metastases, offering a potential therapeutic strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.